Israel Active

Israel’s MeMed (see previously) has been awarded nearly $727,800 from the US Biomedical Advanced Research and Development Authority (BARDA) to support a trial of its 15-minute MeMed BV test that distinguishes between bacterial and viral infections.

The US FDA has approved the VasQ External Vascular Support from Israel’s Laminate Medical Technologies (see previously). It follows a US 144-patients study. VasQ safely connects a patient’s arteries and veins to dialysis machines, by creating arteriovenous fistulas or AVFs.

The SmartHeart monitoring system from Israel’s SHL Telemedicine (see previously) is undergoing trials at Imperial College London. It has reduced ER visits by 27.5% and hospital readmission rates by 55%, surpassing expectations.

A trial of the PROphet blood test from Israel’s OncoHost (see previously) has proved its accuracy and reliability in predicting the best treatment for metastatic non-small cell lung cancer (NSCLC) patients. OncoHost has received orders from 29 US cancer centers since its 2023 launch.

Israel’s PhaseV develops causal machine learning (ML) technology that optimizes clinical trial design and analysis. Its goal is to prevent bio-techs wasting money on failed or badly designed trials of new treatments.  It boosts clinical trial success rates while maximizing resource and time efficiency.

Israel’s mana.bio harnesses the power of AI to significantly reduce development times for new nucleic acid therapeutics and vaccines. Mana.bio produces novel lipid nanoparticles (LNPs) that deliver RNA and gene therapies to specific tissues in the body near to the liver,

Israel’s Sheba Medical Center is using innovative methods to treat the complex injuries suffered by those wounded by Hamas terrorists. One example is the AI systems from Israel’s Aidoc (see previously), used to analyze brain aneurysms from gunshot wounds and rocket shrapnel.

The ElectroGear device from Israel’s Healables (see previously) was designed to enhance performance and accelerate recovery among athletes. It is now being repurposed to treat pain and injuries suffered by IDF personnel. You can even help towards donating one to an Israeli soldier.

The US FDA has approved the QLOSI eye drops, from Israel’s Orasis (see previously), The prescription eye drops improve farsightedness (presbyopia) for up to eight hours without impacting distance or night vision. The treatment can benefit almost two billion sufferers.

Israel’s Teva is partnering with France’s Sanofi (see also ) to develop and commercialize TEV 574, currently in Phase 2b clinical trials, for the anti-TL1A treatment of ulcerative colitis and Crohn's Disease, two types of inflammatory bowel disease (IBD).